Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHL7OB)

Drug Name
Uracil mustard Drug Info
Synonyms
Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Approved [1]
Chronic myelogenous leukaemia 2A20.0 Approved [2]
Polycythemia vera 2A20.4 Approved [2]
Small lymphocytic lymphoma 2A82.0 Approved [2]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
6194
ChEBI ID
CHEMBL9884
CAS Number
CAS 66-75-1
TTD Drug ID
DMHL7OB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Human Deoxyribonucleic acid (hDNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [5]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [6]
Daunorubicin DMQUSBT Acute monocytic leukemia Approved [7]
Ifosfamide DMCT3I8 Adult central nervous system germ cell tumor Approved [8]
Cyclophosphamide DM4O2Z7 Advanced cancer 2A00-2F9Z Approved [9]
Carboplatin DMG281S Adenocarcinoma 2D40 Approved [10]
Busulfan DMXYJ9C Chronic myelogenous leukaemia 2A20.0 Approved [11]
Procarbazine DMIK367 Hodgkin lymphoma 2B30 Approved [12]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [13]
Dacarbazine DMNPZL4 Adenocarcinoma 2D40 Approved [14]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Azacitidine DMTA5OE Acute myelogenous leukaemia 2A41 Approved [15]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [16]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [17]
Drug(s) Affected By Poly polymerase 1 (PARP1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Paclitaxel DMLB81S Breast carcinoma Approved [4]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1) OT7FBG5W NAR1_HUMAN Drug Response [4]
Poly polymerase 1 (PARP1) OTIESHK4 PARP1_ARATH Drug Response [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7621).
2 Uracil mustard FDA Label
3 Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8.
4 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
5 Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
6 Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
7 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
8 Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
9 O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
10 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
11 DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
12 Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
13 Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
14 Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
15 The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
16 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
17 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.